Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Medical Oncology, 2010
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD: Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas Diabetes Care 37 (7): 1910-7,2014.
Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF: Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study Cancer Biology and Therapeutics 15 (6): 683-7,2014.
Keefe SM, Hennessy M, Gunnarsson O, Mamtani R, Vaughn D, Hoffman-Censits Jean, Nathanson KL, Lal P, Pryma D, Eliasof S, Garmey E, Cohen RB, Haas NB: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab in refractory metastatic renal cell carcinoma - results from the planned interim analysis American Association of Cancer Research (AACR) 2014 Annual Meeting : 2014.
Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn DJ, Keefe SM, Guzzo T, Malkowicz SB, Christodouleas JP: Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation International Journal of Radiation Oncology, Biology and Physics 88 (3): 2014.
Keefe SM, Rosen MA, Robinson J, McGibney K, Marshall A, Mamtani R, Vaughn DJ, O'Dwyer PJ, Haas NB, Pryma DA: Results of a feasibility study of I-124 girentuximab (Wilex AB) in metastatic clear cell renal cell carcinoma (m ccRCC) 2014 GU Cancers Symposium ASCO Supplement : 2014.
Brose MS, Frenette CT, Keefe SM, Stein SM: Management of sorafenib-related adverse events: a clinician's perspective Seminars in Oncology Suppl 2 : S1-S16,2014.
Keefe SM, Heitjan D, Hennessey M, Robinson J, Mykulowicz K, Marshall A, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Lal P, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB: Interim Results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 (Cerulean Pharma, Inc., Cambridge, MA, USA) with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC) 2014 GU Cancers Symposium ASCO Supplement : 2014.
Keefe SM, Nathanson KL, Rathmell WK: Molecular biology of renal cell carcinoma Seminars in Oncology 40 (4): 421-8,2013.
Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ: Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy BJU Int 112 (1): 13-25,2013.
Keefe SM, Cohen R, Eliasof S, Garmey EG, Mykulowicz KM, Pryma D, Haas NB: A Phase Ib-IIa Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab in the Treatment of Patients with Advanced Renal Cell Carcinoma (NCT01625936) 2013 Association of American Cancer Research : 2013.
Perelman Center for Advanced Medicine 3400 Civic Center Blvd10th Floor, South Pavilion
Phone: (215) 662-6319
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.